Ignite Creation Date:
2024-05-06 @ 2:40 PM
Last Modification Date:
2024-10-26 @ 1:35 PM
Study NCT ID:
NCT04395066
Status:
UNKNOWN
Last Update Posted:
2020-05-20
First Post:
2020-05-15
Brief Title:
Molecular Diagnosis and Prognosis of Severe Pulmonary Infection Immunosuppressed Hosts
Sponsor:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Organization:
Shanghai General Hospital Shanghai Jiao Tong University School of Medicine
Study Overview
Official Title:
Molecular Diagnosis and Prognosis of Severe Pulmonary Infection in Immunosuppressed Hosts
Status:
UNKNOWN
Status Verified Date:
2020-05
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Serious pneumonia is a serious inflammation of the lungs caused by various pathogens resulting in severe bacteraemia or toxemia which in turn causes blood pressure drop shock blurred consciousness restlessness delirium and coma etc and requires intensive care and treatment in intensive care unit ICU because of its seriousness There is an upward trend in the number of clinically immunosuppressed host patients including long-term use of glucocorticoids for rheumatoid immune diseases and kidney diseases tumor chemotherapy organ transplantation etc A huge risk for these patients is the diagnosis and treatment of infections especially lung infections We have previously observed a significant increase in mortality from severe pneumonia in immunosuppressed patients and our recent analysis of 204 patients with novel coronavirus pneumonia found that low lymphatic counts immunosuppression etc were independent risk factors for death in patients Early diagnosis and timely treatment are the main means to reduce the mortality rate of severe pneumonia CD55 is an important complement regulatory protein that inhibits C3 and C5 activation by blocking the formation and accelerating the decay of new C3 and C5 convertases both of which mediate the downstream action of all three complement activation pathways and CD55 protects host cells from complement attack Our previous study found that CD55 was significantly elevated in patients with severe pneumonia Therefore this project proposes Early diagnosis of severe pneumonia based on combination of biomarkers with new generation pathogenesis and early clinical manifestations It is proposed to validate the predictive effects of recently discovered markers such as CD55 HBP and CD64 on severe pneumonia through prospective single-center clinical studies explore the establishment of new predictive models for early diagnosis of severe pneumonia and optimize the diagnosis and treatment strategy of severe pneumonia and provide new ideas for accurate treatment of severe pneumonia
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None